(0.29%) 5 169.75 points
(0.25%) 38 928 points
(0.27%) 18 049 points
(1.06%) $78.94
(0.47%) $2.15
(0.95%) $2 330.50
(2.67%) $27.40
(1.12%) $976.10
(-0.02%) $0.929
(-0.21%) $10.85
(-0.24%) $0.795
(0.06%) $91.50
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
0.00% HKD 9.20
Live Chart Being Loaded With Signals
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China...
Stats | |
---|---|
Volumen de hoy | 500.00 |
Volumen promedio | 9 910.00 |
Capitalización de mercado | 4.41B |
Próxima fecha de ganancias | ( HKD0 ) 2024-05-08 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -7.13 |
ATR14 | HKD0 (0.00%) |
Jiangsu Recbio Technology Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Jiangsu Recbio Technology Finanzas
Annual | 2023 |
Ingresos: | HKD30.38M |
Beneficio Bruto: | HKD22.34M (73.54 %) |
EPS: | HKD-1.190 |
FY | 2023 |
Ingresos: | HKD30.38M |
Beneficio Bruto: | HKD22.34M (73.54 %) |
EPS: | HKD-1.190 |
FY | 2022 |
Ingresos: | HKD5.33M |
Beneficio Bruto: | HKD5.33M (100.00 %) |
EPS: | HKD-1.520 |
FY | 2021 |
Ingresos: | HKD0.00 |
Beneficio Bruto: | HKD0.00 (0.00 %) |
EPS: | HKD-1.372 |
Financial Reports:
No articles found.
Jiangsu Recbio Technology
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico